Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced an oral presentation at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016that further characterized the efficacy and safety of Vascepa® (icosapent ethyl) in statin-treated women with persistent high triglyceride levels.
The presentation of additional data from the ANCHOR study showed, consistent with overall study results, that prescription pure EPA Vascepa® (icosapent ethyl) reduced triglyceride levels and several other potentially atherogenic lipid parameters and inflammatory markers in a subgroup of statin-treated women with persistent high triglycerides. The post hoc analysis supporting the efficacy of pure, prescription icosapent ethyl in this patient population was presented as an oral abstract (#309) titled, “Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-Treated Women With Persistent High Triglycerides: Results From the ANCHOR Study.”
The analysis was led by Lori Mosca, MD, MPH, PhD, Professor of Medicine Emerita and Center Director of the American Heart Association Go Red for Women Research Network at Columbia University Medical Center, New York. Researchers observed that compared to placebo, Vascepa administered at 4 g/day significantly reduced triglycerides (TGs) without increasing LDL (“bad”) cholesterol in women from the ANCHOR study with TG levels between 200 to 499 mg/dL. In addition, statistically significant improvements were observed in numerous potentially atherogenic parameters (lipids and lipoproteins) and inflammatory markers.
“It is important to generate data that address the specific needs of women, especially in fields where the data could prove useful to patient care,” said Dr. Mosca. “While further study is needed and ongoing, this analysis is encouraging because the efficacy and safety of Vascepa 4 g/day in this subgroup of 91 statin-treated women with persistent high triglycerides were consistent with the overall ANCHOR results, which included 702 patients. It is vitally important to evaluate both potential benefits and side effects of therapies in women and not assume results from men are similar in women.”
The clinical implications of lowering triglycerides with Vascepa 4 g/day are being investigated in the REDUCE-IT cardiovascular outcomes study of statin-treated women and men with persistent elevated TG levels.
The ANCHOR study and post hoc analysis were sponsored by Amarin and were not affiliated with or funded by the American Heart Association (AHA) or the AHA Go Red for Women Research Network. (Original Source)
Shares of Amarin are up nearly 2% to $3.35 in pre-market trading Tuesday. AMRN has a 1-year high of $3.65 and a 1-year low of $1.24. The stock’s 50-day moving average is $3.12 and its 200-day moving average is $2.52.
On the ratings front, Amarin has been the subject of a number of recent research reports. In a report issued on November 3, Cantor analyst Chiara Russo reiterated a Buy rating on AMRN, with a price target of $6.00, which represents a potential upside of 83% from where the stock is currently trading. Separately, on the same day, Jefferies’ Hugo Ong reiterated a Buy rating on the stock and has a price target of $4.50.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Chiara Russo and Hugo Ong have a yearly average return of 3.8% and 9.8% respectively. Russo has a success rate of 54% and is ranked #907 out of 4214 analysts, while Ong has a success rate of 68% and is ranked #872.
Amarin Corp. Plc is a biopharmaceutical company, which engages in the commercialization and development of therapeutics for cardiovascular health. It has developed and markets Vascepa capsules through wholesale.